Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Core Insights - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD) [1][3] - The company announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, highlighting the efficacy of its drug Rademikibart in treating eosinophilic driven, Type 2 asthma [1][2] Company Overview - Connect Biopharma is headquartered in San Diego, California, and is dedicated to advancing Rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody [3] - The company targets acute exacerbations in asthma and COPD, addressing a significant unmet need among approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually [3] Clinical Trial Highlights - Rademikibart demonstrated strong efficacy and safety data in a Phase 2 trial for asthma, showing clinically meaningful reductions in exacerbations [3] - Rapid, statistically significant improvements in forced expiratory volume in one second (FEV1) were observed within one week, and in most cases, within 24 hours via home spirometry [3] Presentation Details - The presentations at the EAACI Congress will cover the reduction in annualized exacerbations and improvement in lung function with Rademikibart in eosinophilic driven, Type 2 asthma [2]